Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 12/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2405156 | 0.82 | CCR5 (0.60) | CCR5KCNH2GPR119SIGMAR1 | |
| SCHEMBL2407533 | 0.82 | KCNH2 (0.49) | CCR5KCNH2GPR119SIGMAR1 | |
| SCHEMBL13434079 | 0.80 | CCR5 (0.63) | CCR5KCNH2SIGMAR1 | |
| SCHEMBL2405257 | 0.78 | CCR5 (0.62) | CCR5SIGMAR1 | |
| SCHEMBL2408897 | 0.78 | KCNH2 (0.69) | CCR5KCNH2GPR119 | |
| SCHEMBL1512619 | 0.77 | KCNH2 (0.47) | CCR5KCNH2GPR119 | |
| SCHEMBL2405481 | 0.76 | CCR5 (0.52) | CCR5SIGMAR1 | |
| SCHEMBL27835426 | 0.76 | CCR5 (0.64) | CCR5KCNH2GPR119SIGMAR1 | |
| SCHEMBL2404555 | 0.75 | CCR5 (0.44) | CCR5KCNH2GPR119SIGMAR1 | |
| SCHEMBL14297341 | 0.75 | NPC1 (0.55) | CCR5KCNH2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | CCR5 2055/4885KCNH2 498/4885GPR119 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.